Escitalopram + Etizolam Tablets - ESICARE-EZ

ESICARE-EZ is a specialized oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Escitalopram Oxalate IP equivalent to Escitalopram 10 mg combined with Etizolam IP 0.5 mg, formulated to treat major depression comorbid with acute anxiety, somatic tension, panic symptoms, and sleep disturbances.

Etizolam is a thienodiazepine analogue that exhibits high affinity for GABA_A receptor subunits with a rapid onset of action (30-60 minutes) and an intermediate elimination half-life (around 6-8 hours). Unlike long-acting benzodiazepines such as Clonazepam (half-life 30-40 hours), Etizolam relieves acute distress and facilitates sleep with lower risk of next-day morning hangover or daytime cognitive sluggishness.

Escitalopram 10 mg selectively inhibits SERT, preventing serotonin reabsorption to elevate mood and restore cognitive drive over 2 to 4 weeks. Simultaneously, Etizolam 0.5 mg immediately enhances GABAergic inhibitory neurotransmission, blocking sympathetic hyperarousal and panic surges from the very first dose.

Psychiatrists typically advise taking ESICARE-EZ once daily, either in the evening or at bedtime with water. Bedtime administration is common if the patient has difficulty falling asleep or suffers from nighttime anxiety awakenings.

While Etizolam has a cleaner clearance profile than classical benzodiazepines, mild drowsiness, relaxation, or lightheadedness can still occur, particularly during initial days of therapy. Patients should avoid driving or hazardous tasks until they know how the medication affects them.

No. Abrupt stoppage of either Escitalopram or Etizolam can precipitate withdrawal symptoms including rebound anxiety, restlessness, insomnia, and sensory disturbances. Discontinuation must be carried out through a gradual dose tapering protocol under direct medical supervision.

Alcohol is strictly prohibited. Combining alcohol with Escitalopram and Etizolam can cause additive central nervous system depression, extreme sedation, respiratory impairment, and impaired motor coordination.

Etizolam has potential for dependence and tolerance if used for prolonged durations without medical oversight. Clinicians generally use it for short-to-medium term anxiety relief while Escitalopram's full antidepressant efficacy is established.

Common side effects include mild sedation, headache, dry mouth, nausea, changes in appetite, or mild dizziness. Most side effects are transient and diminish over the first week or two of consistent therapy.

Use during pregnancy or lactation is generally contraindicated unless strictly evaluated and deemed vital by a specialist, as both Escitalopram and Etizolam can cross the placental barrier and enter breast milk.

ESICARE-EZ is supplied in protective 10x10 blister strips (100 tablets per box) manufactured with tropicalized foil packaging to prevent humidity and light damage across varied climatic regions in India.

Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.

Yes. Dellwich Lifescience provides turnkey contract manufacturing for Escitalopram + Etizolam combinations with WHO-GMP certification, customized branding, and fast dispatch from Ahmedabad.

Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid nationwide logistics connections to supply distributors and healthcare providers across all Indian states.